These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35434840)

  • 1. Methyltransferase-like 3 promotes the progression of lung cancer via activating PI3K/AKT/mTOR pathway.
    Cheng FW; Peng LM; Luo D
    Clin Exp Pharmacol Physiol; 2022 Jul; 49(7):748-758. PubMed ID: 35434840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
    Bi X; Lv X; Liu D; Guo H; Yao G; Wang L; Liang X; Yang Y
    Cancer Gene Ther; 2021 Apr; 28(3-4):335-349. PubMed ID: 32939058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YTHDF1 Promotes Bladder Cancer Cell Proliferation via the METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR Axis.
    Zhu J; Tong H; Sun Y; Li T; Yang G; He W
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC.
    Cao Y; Di X; Cong S; Tian C; Wang Y; Jin X; Zhao M; Zhou X; Li R; Wang K
    Life Sci; 2023 Feb; 315():121359. PubMed ID: 36608868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of epigenetic m
    Parial R; Li H; Li J; Archacki S; Yang Z; Wang IZ; Chen Q; Xu C; Wang QK
    FASEB J; 2021 May; 35(5):e21465. PubMed ID: 33788967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. METTL3-mediated m
    Zhou YF; Li JT; Zheng QL; Ren KL; Yi CC
    Kaohsiung J Med Sci; 2024 Feb; 40(2):150-160. PubMed ID: 38088510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3-mediated m6A modification of EPPK1 to promote the development of esophageal cancer through regulating the PI3K/AKT pathway.
    Jia J; Yu L
    Environ Toxicol; 2024 May; 39(5):2830-2841. PubMed ID: 38293837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation.
    Lin C; Li T; Wang Y; Lai S; Huang Y; Guo Z; Zhang X; Weng S
    Cell Death Dis; 2023 Mar; 14(3):221. PubMed ID: 36977668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling.
    Liu X; He H; Zhang F; Hu X; Bi F; Li K; Yu H; Zhao Y; Teng X; Li J; Wang L; Zhang Y; Wu Q
    Cell Death Dis; 2022 May; 13(5):483. PubMed ID: 35595748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway.
    Cui S
    J Clin Lab Anal; 2022 Dec; 36(12):e24761. PubMed ID: 36336887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL3-Mediated m
    Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
    Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma.
    Gao F; Wang Q; Zhang C; Zhang C; Qu T; Zhang J; Wei J; Guo R
    J Cell Mol Med; 2021 Mar; 25(5):2418-2425. PubMed ID: 33491264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. m
    Zhang H; Zhang P; Long C; Ma X; Huang H; Kuang X; Du H; Tang H; Ling X; Ning J; Liu H; Deng X; Zou Y; Wang R; Cheng H; Lin S; Zhang Q; Yan J; Shen H
    J Cell Mol Med; 2020 Nov; 24(21):12368-12378. PubMed ID: 33090698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL3 exerts synergistic effects on m6A methylation and histone modification to regulate the function of VGF in lung adenocarcinoma.
    Shi K; Sa R; Dou L; Wu Y; Dong Z; Fu X; Yu H
    Clin Epigenetics; 2023 Sep; 15(1):153. PubMed ID: 37742030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-dependent manner.
    Chen J; Zhang H; Xiu C; Gao C; Wu S; Bai J; Shen Q; Yin T
    Cancer Lett; 2023 Jul; 565():216222. PubMed ID: 37196908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway.
    Liu X; Xiao M; Zhang L; Li L; Zhu G; Shen E; Lv M; Lu X; Sun Z
    J Clin Lab Anal; 2021 Mar; 35(3):e23655. PubMed ID: 33314339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METTL3 Attenuates Inflammation in Fusarium solani-Induced Keratitis via the PI3K/AKT Signaling Pathway.
    Huang L; Tang H; Hu J
    Invest Ophthalmol Vis Sci; 2022 Sep; 63(10):20. PubMed ID: 36169946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 contributes to slow transit constipation by regulating miR-30b-5p/PIK3R2/Akt/mTOR signaling cascade through DGCR8.
    Gong WJ; Li R; Dai QQ; Yu P
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2229-2242. PubMed ID: 36068012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.